

1648  
ihs

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 18, 2004.

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1648  
Patent Application  
Docket No. USF-T156X  
Serial No. 10/073,065

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Zachariah Lucas  
Art Unit : 1648  
Applicants : Shyam Mohapatra, Mukesh Kumar, Shau-Ku Huang, Kam W. Leong  
Serial No. : 10/073,065  
Filed : February 12, 2002  
Conf. No. : 2390  
For : Gene Expression Vaccine

MS AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/073,065	
			Filing Date	February 12, 2002	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1648	
			Examiner Name	Zachariah Lucas	
Sheet	1	of	1	Attorney Docket Number	USF-T156X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	MAO, H.Q. <i>et al.</i> "DNA-chitosan nanospheres for gene delivery" in International Symposium on Controlled Release of Bioactive Materials, 23(1996), Kyoto, Japan, Controlled Release Society; abstract no. 4138, p. 401.	
	R2	MAO, H.Q. <i>et al.</i> "DNA-chitosan nanospheres: derivatization and storage stability" in International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract no. 6016, p. 671.	
	R3	WALSH, S.M. <i>et al.</i> "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis" in Proceedings of the International Conference on Controlled Release of Bioactive Agents, 24(1997), Stockholm, Sweden, abstract no. 238, p. 75.	
	R4	TRUONG-LE, V.L. <i>et al.</i> "Delivery of DNA vaccine using gelatin-DNA nanospheres" in International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract no. 219, p. 39.	
	R5	ROY, K. <i>et al.</i> "DNA-chitosan nanospheres: transfection efficiency and cellular uptake" in International Symposium on Controlled Release of Bioactive Materials, 24(1997), Stockholm, Sweden, Controlled Release Society, abstract no. 6017, p. 673.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.